DOSING AND SCHEDULING GUIDE

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.



When patients with chronic liver disease and thrombocytopenia are scheduled for a procedure, don't expose them to unnecessary bleeding risk.

CONFRONT THE RISKS OF BLEEDING HEAD ON. HELP PROTECT YOUR PATIENTS WITH DOPTELET.

DOPTELET significantly reduced the need for platelet transfusions or rescue procedures for bleeding for up to 7 days post procedure.[1]*

*From randomization of DOPTELET 40 mg or DOPTELET 60 mg once daily for 5 days up to 7 days after a procedure, compared to placebo ($P<.001$; N=435).

SELECTED IMPORTANT SAFETY INFORMATION

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Doptelet® (avatrombopag) tablets

Please see Selected Important Safety Information on back cover and accompanying Full Prescribing Information for DOPTELET (avatrombopag), also available at DOPTELET.com.

Right Dose to Target the Right Response[1]

Two dosing options based on your patient's baseline platelet count

- **For High-Baseline Platelet Count 40,000 to <50,000/µL**
- **40 mg (2 tablets)** once daily with food

- **For Low-Baseline Platelet Count <40,000/µL**
- **60 mg (3 tablets)** once daily with food

Patients should start DOPTELET 10 to 13 days prior to a scheduled procedure

DAYS 1-5	**TAKE DOPTELET ONCE DAILY FOR 5 DAYS WITH FOOD**	**1x DAILY WITH FOOD**
DAYS 6-9	WAIT 4 DAYS FOR PLATELET COUNT TO RISE	WAITING PERIOD
DAYS 10-13	**4-DAY PROCEDURE WINDOW**	**PROCEDURE WINDOW**

- **In the case of a missed dose,** patients should take the next dose of DOPTELET as soon as they remember
- Patients should not take 2 days of dosing at one time to make up for a missed dose and should take the next dose at the usual time the next day
- All 5 days of dosing should be completed
- **Monitoring:** Obtain a platelet count prior to administration of DOPTELET therapy and on the day of a procedure to ensure an adequate increase in platelet count

Please see Selected Important Safety Information on back cover and accompanying Full Prescribing Information for DOPTELET (avatrombopag), also available at DOPTELET.com.

Get Patients Started on DOPTELET With Support From Dova 1Source

Dova 1Source is the single point of contact to access DOPTELET, providing patients with the resources they need, including a network of specialty pharmacies and financial support programs.

Dova PHARMACEUTICALS 1SOURCE™

1-833-DOVA-ONE
(1-833-368-2663)

Learn more at Dova1Source.com

INDICATION

DOPTELET (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

SELECTED IMPORTANT SAFETY INFORMATION

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Contraindications: None

Adverse Reactions

The most common adverse reactions (≥3%) were: pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.

To report suspected adverse reactions, contact Dova Pharmaceuticals at 1-844-506-DOVA (3682) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying Full Prescribing Information for DOPTELET (avatrombopag), also available at DOPTELET.com.

REFERENCE: 1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc; 2018.

Doptelet® (avatrombopag) tablets